Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024
Lucid Diagnostics (Nasdaq: LUCD) announced its participation in The MedTech Conference 2024, scheduled for October 15-17 in Toronto, Canada. The company will showcase its EsoGuard® and EsoCheck® technologies in the conference's Innovation Pavilion, offering live demonstrations to attendees. Lishan Aklog, M.D., Lucid's Chairman and CEO, will participate in a CEOs Unplugged event alongside industry leaders. Additionally, Shaun O'Neil, Lucid's President and COO, will deliver the company's presentation at the conference's Investor Forum.
Lucid's presence at the conference, organized by AdvaMed, provides an opportunity to engage with industry leaders, potential partners, and investors. The event is expected to attract over 1,500 companies and attendees from 45 countries, highlighting its significance in the medical technology industry.
Lucid Diagnostics (Nasdaq: LUCD) ha annunciato la sua partecipazione a The MedTech Conference 2024, in programma dal 15 al 17 ottobre a Toronto, Canada. L'azienda presenterà le sue tecnologie EsoGuard® e EsoCheck® nel Pavilion dell'Innovazione della conferenza, offrendo dimostrazioni dal vivo ai partecipanti. Lishan Aklog, M.D., Presidente e CEO di Lucid, parteciperà a un evento CEOs Unplugged insieme ai leader del settore. Inoltre, Shaun O'Neil, Presidente e COO di Lucid, terrà la presentazione dell'azienda al Forum per gli Investitori della conferenza.
La presenza di Lucid alla conferenza, organizzata da AdvaMed, offre l'opportunità di interagire con leader del settore, partner potenziali e investitori. Si prevede che l'evento attrarrà oltre 1.500 aziende e partecipanti da 45 paesi, sottolineando la sua importanza nell'industria della tecnologia medica.
Lucid Diagnostics (Nasdaq: LUCD) anunció su participación en The MedTech Conference 2024, programada para el 15-17 de octubre en Toronto, Canadá. La empresa exhibirá sus tecnologías EsoGuard® y EsoCheck® en el Pabellón de Innovación de la conferencia, ofreciendo demostraciones en vivo a los asistentes. Lishan Aklog, M.D., Presidente y CEO de Lucid, participará en un evento CEOs Unplugged junto a líderes de la industria. Además, Shaun O'Neil, Presidente y COO de Lucid, presentará la compañía en el Foro de Inversores de la conferencia.
La presencia de Lucid en la conferencia, organizada por AdvaMed, brinda una oportunidad para interactuar con líderes de la industria, socios potenciales e inversores. Se espera que el evento atraiga a más de 1,500 empresas y participantes de 45 países, destacando su importancia en la industria de la tecnología médica.
루시드 진단학 (나스닥: LUCD)이 2024 메드테크 컨퍼런스에 참가한다고 발표했으며, 행사는 10월 15일부터 17일까지 캐나다 토론토에서 개최됩니다. 이 회사는 EsoGuard® 및 EsoCheck® 기술을 컨퍼런스의 혁신 파빌리온에서 선보이며, 참석자들에게 실시간 시연을 제공합니다. 리샨 악클록, M.D., 루시드의 회장 겸 CEO는 업계 리더들과 함께 CEO 언플러그드 이벤트에 참여할 예정입니다. 또한, 숀 오닐, 루시드의 사장 겸 COO는 컨퍼런스의 투자자 포럼에서 회사 발표를 할 것입니다.
루시드의 컨퍼런스 참석은 AdvaMed가 주최하며, 업계 리더, 잠재적 파트너 및 투자자들과의 교류 기회를 제공합니다. 이 행사는 45개국에서 1,500개 이상의 회사와 참석자들을 끌어모을 것으로 예상되며, 의료 기술 산업에서의 중요성을 강조합니다.
Lucid Diagnostics (Nasdaq: LUCD) a annoncé sa participation à The MedTech Conference 2024, prévue du 15 au 17 octobre à Toronto, Canada. L'entreprise mettra en avant ses technologies EsoGuard® et EsoCheck® dans le Pavillon de l'Innovation de la conférence, proposant des démonstrations en direct aux participants. Lishan Aklog, M.D., Président et CEO de Lucid, participera à un événement CEOs Unplugged aux côtés de leaders du secteur. De plus, Shaun O'Neil, Président et COO de Lucid, fera la présentation de l'entreprise lors du Forum des Investisseurs de la conférence.
La présence de Lucid à la conférence, organisée par AdvaMed, offre une opportunité d'interagir avec des leaders du secteur, des partenaires potentiels et des investisseurs. L'événement devrait attirer plus de 1 500 entreprises et participants de 45 pays, soulignant son importance dans l'industrie de la technologie médicale.
Lucid Diagnostics (Nasdaq: LUCD) hat seine Teilnahme an Der MedTech-Konferenz 2024 angekündigt, die vom 15. bis 17. Oktober in Toronto, Kanada, stattfindet. Das Unternehmen wird seine Technologien EsoGuard® und EsoCheck® im Innovationspavillon der Konferenz präsentieren und den Teilnehmern Live-Demonstrationen anbieten. Lishan Aklog, M.D., Vorstandsvorsitzender und CEO von Lucid, wird an einem CEOs Unplugged-Event zusammen mit Branchenführern teilnehmen. Außerdem wird Shaun O'Neil, Präsident und COO von Lucid, die Unternehmenspräsentation im Investor Forum der Konferenz halten.
Lucids Anwesenheit auf der Konferenz, die von AdvaMed organisiert wird, bietet die Möglichkeit, mit Branchenführern, potenziellen Partnern und Investoren in Kontakt zu treten. Die Veranstaltung wird voraussichtlich über 1.500 Unternehmen und Teilnehmer aus 45 Ländern anziehen und unterstreicht ihre Bedeutung in der Medizintechnologiebranche.
- Lucid Diagnostics selected to showcase its technologies in the prestigious Innovation Pavilion
- Company's CEO participating in high-profile CEOs Unplugged event alongside industry leaders
- Opportunity to demonstrate EsoGuard® and EsoCheck® technologies to a wide audience of potential partners and investors
- Strong presence throughout the conference, including a company presentation at the Investor Forum
- None.
Company to showcase EsoGuard® and EsoCheck® at the conference's Innovation Pavilion
Innovation Pavilion
Lucid has been selected to participate in the conference's prestigious Innovation Pavilion, a dedicated area within the MedTech Campus for device, diagnostic, and digital health companies to showcase their cutting-edge technologies. The Lucid team, led by Jessie Gifford, Lucid's Senior Director of Product Development & Manufacturing, will host live demonstrations of Lucid's EsoCheck® Esophageal Cell Collection Device and showcase the performance of its EsoGuard® Esophageal DNA Test, allowing conference attendees to experience firsthand how these innovative technologies seek to prevent esophageal cancer through widespread, early detection of esophageal precancer in at-risk patients.
CEOs Unplugged Event
Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will be featured at one of the conference's CEOs Unplugged events where he will be joined by distinguished panelists, including
- Caroline Irungu, Global VP of Medtech at Dassault Systemes;
- Jaime Wheeler, VP of Global Clinical Affairs at Edwards Lifesciences; and
- Jean-Claude Dubacher, Chairman and Chief Executive Officer of B. Braun of America Inc.
Dr. Aklog proudly represents Lucid and PAVmed in several key leadership positions within the AdvaMed organization. As a member of the Executive Committee of the AdvaMed Board of Directors, he contributes to strategic initiatives that advance the medical technology sector. He also serves on the AdvaMedDx Board of Directors, which focuses on the vital interests of diagnostic companies and as Chairman of the AdvaMed Accel Board of Directors, which supports the growth and development of small medical technology companies, such as Lucid.
Company Presentation
As part of the conference's Investor Forum, Shaun O'Neil, Lucid's President and Chief Operating Officer, will deliver Lucid's Company Presentation on Tuesday, October 15, 2024, from 3:45-3:55 PM.
"The MedTech Conference has become the world's leading annual event for the medical technology industry and offers Lucid the opportunity to engage with industry leaders, potential strategic partners, and investors who are shaping the future of healthcare," said Dr. Aklog. "We are excited to have been selected to exhibit in the Innovation Pavilion, where we will showcase our groundbreaking technologies, EsoGuard and EsoCheck, and to have a strong presence throughout the conference."
The MedTech Conference, organized by AdvaMed (the Advanced Medical Technology Association), is the premier annual event for the medical technology industry, with over 1,500 companies and attendees from 45 countries expected to participate this year. AdvaMed is the world largest medical technology association, representing over 500 companies that produce medical devices, diagnostic products, and health information systems. AdvaMed advocates for patient access to safe, effective, and innovative technologies that save and improve lives.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information about Lucid, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.
Forward-Looking Statements
This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid's common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid's clinical and preclinical studies; whether and when Lucid's products are cleared by regulatory authorities; market acceptance of Lucid's products once cleared and commercialized; Lucid's ability to raise additional funding as needed; and other competitive developments. In addition, Lucid continues to monitor the COVID-19 pandemic and the pandemic's impact on Lucid's businesses. These factors are difficult or impossible to predict accurately and many of them are beyond Lucid's control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid's future operations, see Part I, Item 1A, "Risk Factors," in Lucid's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report. Lucid disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-join-global-medtech-leaders-at-the-medtech-conference-2024-302269914.html
SOURCE Lucid Diagnostics
FAQ
What technologies will Lucid Diagnostics (LUCD) showcase at The MedTech Conference 2024?
When and where will The MedTech Conference 2024 take place?
Who will represent Lucid Diagnostics (LUCD) at the CEOs Unplugged event during the conference?